Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents

Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/ mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu, Wan, Wen-zhu, Li, Yan, Zhou, Guan-lian, Liu, Xin-guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351699/
https://www.ncbi.nlm.nih.gov/pubmed/27769061
http://dx.doi.org/10.18632/oncotarget.12742
_version_ 1782514817299382272
author Liu, Yu
Wan, Wen-zhu
Li, Yan
Zhou, Guan-lian
Liu, Xin-guang
author_facet Liu, Yu
Wan, Wen-zhu
Li, Yan
Zhou, Guan-lian
Liu, Xin-guang
author_sort Liu, Yu
collection PubMed
description Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/ mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual inhibitors.
format Online
Article
Text
id pubmed-5351699
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53516992017-04-13 Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents Liu, Yu Wan, Wen-zhu Li, Yan Zhou, Guan-lian Liu, Xin-guang Oncotarget Review Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/ mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual inhibitors. Impact Journals LLC 2016-10-18 /pmc/articles/PMC5351699/ /pubmed/27769061 http://dx.doi.org/10.18632/oncotarget.12742 Text en Copyright: © 2017 Liu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Liu, Yu
Wan, Wen-zhu
Li, Yan
Zhou, Guan-lian
Liu, Xin-guang
Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
title Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
title_full Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
title_fullStr Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
title_full_unstemmed Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
title_short Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
title_sort recent development of atp-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351699/
https://www.ncbi.nlm.nih.gov/pubmed/27769061
http://dx.doi.org/10.18632/oncotarget.12742
work_keys_str_mv AT liuyu recentdevelopmentofatpcompetitivesmallmoleculephosphatidylinostitol3kinaseinhibitorsasanticanceragents
AT wanwenzhu recentdevelopmentofatpcompetitivesmallmoleculephosphatidylinostitol3kinaseinhibitorsasanticanceragents
AT liyan recentdevelopmentofatpcompetitivesmallmoleculephosphatidylinostitol3kinaseinhibitorsasanticanceragents
AT zhouguanlian recentdevelopmentofatpcompetitivesmallmoleculephosphatidylinostitol3kinaseinhibitorsasanticanceragents
AT liuxinguang recentdevelopmentofatpcompetitivesmallmoleculephosphatidylinostitol3kinaseinhibitorsasanticanceragents

Ejemplares similares